The MLL recombinome of acute leukemias in 2017

Claus Meyer(Goethe University Frankfurt), Thomas Burmeister(Charité - Universitätsmedizin Berlin), Daniela Gröger(Charité - Universitätsmedizin Berlin), Grigory Tsaur(Ural Federal University), Л. Г. Фечина(Ural Federal University), Aline Renneville(Inserm), Rosemary Sutton(Children's Cancer Institute Australia), Nicola C. Venn(Children's Cancer Institute Australia), Mariana Emerenciano(Instituto Nacional de Câncer - INCA), Maria S. Pombo‐de‐Oliveira(Instituto Nacional de Câncer - INCA), Caroline Barbieri Blunck(Instituto Nacional de Câncer - INCA), Bruno A. Lopes(Instituto Nacional de Câncer - INCA), Jan Zuna(Charles University), Jan Trka(Charles University), Paola Ballerini(Sorbonne Université), Hélène Lapillonne(Sorbonne Université), Marc De Braekeleer(Inserm), Giovanni Cazzaniga(University of Milano-Bicocca), L Corral Abascal(University of Milano-Bicocca), Vincent H. J. van der Velden(Erasmus MC), Éric Delabesse(Hôpital Purpan), T S Park(Kyung Hee University), Seung Hwan Oh(Inje University), Maria Luiza Macedo Silva(Instituto Nacional de Câncer - INCA), T Lund-Aho(Fimlab (Finland)), Vesa Juvonen(University of Turku), Andrew S. Moore(The University of Queensland), Olaf Heidenreich(Newcastle University), Josef Vormoor(Newcastle upon Tyne Hospitals NHS Foundation Trust), Elena Zerkalenkova(Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology), Yulia Olshanskaya(Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology), Clara Bueno(Institució Catalana de Recerca i Estudis Avançats), Pablo Menéndez(Institució Catalana de Recerca i Estudis Avançats), Andrea Teigler‐Schlegel, Udo zur Stadt(Universität Hamburg), Jana Lentes(Medizinische Hochschule Hannover), Gudrun Göhring(Medizinische Hochschule Hannover), Anatoly Kustanovich(Belarusian Research Center For Pediatric Oncology and Hematology), Olga Aleinikova(Belarusian Research Center For Pediatric Oncology and Hematology), Beat W. Schäfer(University Children's Hospital Zurich), Susanne Kubetzko(University Children's Hospital Zurich), H O Madsen(Rigshospitalet), Bernd Gruhn(Jena University Hospital), Ximo Duarte(Instituto Português de Oncologia Francisco Gentil), Paula Gameiro(Instituto Português de Oncologia Francisco Gentil), Éric Lippert(Inserm), Audrey Bidet(Inserm), J M Cayuela(Délégation Paris 7), Emmanuelle Clappier(Délégation Paris 7), Cristina N. Alonso(Garrahan Hospital), C. Michel Zwaan(Erasmus MC - Sophia Children’s Hospital), Marry M. van den Heuvel‐Eibrink(Erasmus MC - Sophia Children’s Hospital), Shai Izraeli(Tel Aviv University), L. Trakhtenbrot(Tel Aviv University), Paul A. Archer(North Bristol NHS Trust), Jerry Hancock(North Bristol NHS Trust), Anja Möricke(University Hospital Schleswig-Holstein), Julia Alten(University Hospital Schleswig-Holstein), Martin Schrappe(University Hospital Schleswig-Holstein), Martin Stanulla, Sabine Strehl(St Anna Children's Hospital), Andishe Attarbaschi(St Anna Children's Hospital), Michael Dworzak(St Anna Children's Hospital), Oskar A. Haas(St Anna Children's Hospital), R Panzer-Grümayer(St Anna Children's Hospital), Łukasz Sędek(Medical University of Silesia), Tomasz Szczepański(Medical University of Silesia), Aurélie Caye(Délégation Paris 7), Lydia Suarez(Délégation Paris 7), Hélène Cavé(Délégation Paris 7), Rolf Marschalek(Goethe University Frankfurt)
Leukemia
July 13, 2017
Cited by 685Open Access
Full Text

Abstract

Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced acute leukemias. Here we present the data obtained from 2345 acute leukemia patients. Genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and 11 novel TPGs were identified. Thus, a total of 135 different MLL rearrangements have been identified so far, of which 94 TPGs are now characterized at the molecular level. In all, 35 out of these 94 TPGs occur recurrently, but only 9 specific gene fusions account for more than 90% of all illegitimate recombinations of the MLL gene. We observed an age-dependent breakpoint shift with breakpoints localizing within MLL intron 11 associated with acute lymphoblastic leukemia and younger patients, while breakpoints in MLL intron 9 predominate in AML or older patients. The molecular characterization of MLL breakpoints suggests different etiologies in the different age groups and allows the correlation of functional domains of the MLL gene with clinical outcome. This study provides a comprehensive analysis of the MLL recombinome in acute leukemia and demonstrates that the establishment of patient-specific chromosomal fusion sites allows the design of specific PCR primers for minimal residual disease analyses for all patients.


Related Papers

No related papers found

Powered by citation graph analysis